Recommendation of the President – Acarizax (standardized allergen extract of house dust mites, D. pteronyssinus, D. farina)
On 27 June 2024 the President of the Agency for Health Technology Assessment and Tariff System issued the following recommendation No. 63/2024 of the drug Acarizax (standardized allergen extract of house dust mite, D. pteronyssinus, D. farina) for the indication: Treatment of adult patients (18 to 65 years of age) diagnosed on the basis of clinical history and a positive house dust mite allergy test (spot skin tests and/or specific immunoglobulin E) and at least one of the following conditions:
- moderate to severe allergic rhinitis caused by house dust, persisting despite medication to relieve symptoms;
- bronchial asthma caused by house dust allergy, not controlled well with inhaled corticosteroids accompanied by moderate to severe allergic rhinitis caused by house dust
Publication in Public Information Bulletin (BIP) >>